Trial failure may not be the end of the road for solengepras

At the recent AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Disease (PD), Cerevance (Nasdaq: CRNC) announced that solengepras, a first-in-class G-protein coupled receptor 6 (GPR6) antagonist in development for early PD, failed to meet its primary endpoint in the Phase II ASCEND trial as a monotherapy.

However, this does not spell the end of the road for solengepras, because it has shown promise in other clinical trials as an adjunctive therapy, according to GlobalData in an analysis of its prospects.

Jos Opdenakker, neurology analyst at GlobalData, explained: “Solengepras failed to meet its primary endpoint, as patients treated with the drug experienced a small, non-statistically significant improvement from baseline compared to placebo in the MDS-UPDRS Parts II and III combined score at week 12.